Sequent Scientific Reports Mixed Q3 Results Amid Rising Interest Expenses and Non-Operating Income Concerns

Sequent Scientific, a small-cap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The results indicate a mixed performance, with notable developments influencing its evaluation.
On a positive note, the company recorded a Profit Before Tax (PBT) of Rs 2.57 crore, reflecting a significant year-on-year growth of 144.39%. Additionally, net sales reached Rs 390.81 crore, marking the highest figure in the last five quarters, suggesting a favorable trend in sales performance.

Conversely, the Profit After Tax (PAT) showed a decline, standing at Rs 3.69 crore, which represents a year-on-year decrease of 33.1%. Furthermore, the interest expense for the nine-month period rose to Rs 45.62 crore, indicating an increase in borrowings. The reliance on non-operating income, which constituted 69.44% of PBT, raises concerns about the sustainability of the business model, especially as this income reached its highest level in the last five quarters.

In light of these developments, Sequent Scientific has experienced an adjustment in its evaluation, with its score reflecting the recent changes in financial performance.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.